|
| 肠-肺轴调控肺癌发生发展与免疫机制及临床干预策略 |
| Intestinal-lung axis regulation of lung cancer development and immune mechanisms and clinical intervention strategies |
| 投稿时间：2025-08-05 修订日期：2025-09-11 |
| DOI： |
|
 |
| 中文关键词: 肠-肺轴 肠道菌群 肺癌 免疫调节 代谢调控 |
| 英文关键词:Intestinal-lung axis intestinal flora lung cancer immune regulation metabolic regulation |
| 基金项目:黑龙江省中医药科研项目：国医大师学术思想传承科研课题项目（项目编号：GY2022-05） 黑龙江中医药大学附属第一医院国家自然科学基金培育支持计划 面上项目（项目编号：PYMS202501004） |
|
| 摘要点击次数: 176 |
| 全文下载次数: 7 |
| 中文摘要: |
| "肠-肺轴"（Gut-Lung Axis）作为肠道菌群与远端肺部疾病之间的关键桥梁，已成为肿瘤免疫研究的前沿领域。本文系统综述了肠道菌群通过免疫调节、代谢产物介导及系统性炎症途径调控肺癌发生、发展及免疫治疗应答的分子机制。重点分析了肠道微生物组作为预测免疫检查点抑制剂（Immune Checkpoint Inhibitors, ICIs）疗效的生物标志物价值，并深入探讨了基于微生物组的干预策略，如粪菌移植（Fecal Microbiota Transplantation, FMT）、益生菌、益生元及饮食调整的临床前与临床研究进展。文章还批判性评估了III期临床研究对肠道菌群作用的支持证据，并对当前挑战和未来转化方向进行了总结与展望，旨在为肺癌的精准免疫治疗提供新思路。 |
| 英文摘要: |
| The gut-lung axis, a crucial bridge linking gut microbiota and distal pulmonary diseases, has emerged as a frontier in cancer immunology research. This review systematically summarizes the molecular mechanisms through which the gut microbiota regulates lung cancer initiation, progression, and response to immunotherapy via immune modulation, microbial metabolites, and systemic inflammation. It highlights the value of the gut microbiome as a biomarker for predicting the efficacy of immune checkpoint inhibitors (ICIs) and provides an in-depth discussion of microbiome-based interventions—such as fecal microbiota transplantation (FMT), probiotics, prebiotics, and dietary modifications—based on evidence from both preclinical and clinical studies. The article also critically evaluates supporting evidence from phase III clinical trials regarding the role of gut microbiota, addresses current challenges, and outlines future translational directions, aiming to provide new insights for precision immunotherapy in lung cancer. |
|
在线阅读
查看/发表评论 下载PDF阅读器 |
|
|
|